

Access DB#

280715

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Leah Schlietz Examiner #: 1 Date: 12/15/08
 Art Unit: 1618 Phone Number: 202-9928 Serial Number: 10/551,292
 Mail Box and Bldg/Room Location: Fern 70 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Bifunctional tridentate pyrazolyl containing ligands
 Inventors (please provide full names): Isabel Santos, Joao Domingos Correia, for
António Paulo, Susana Alves, Rute Vitor Re
 and
 Earliest Priority Filing Date: 4/15/2004 Tc

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Structure
 search

- especially claims

#1, 24, 25, 26, 36, 38


and 50-52.

Trisubstituted
 complexes

10/551,292

Structure uploaded into STN REGISTRY

Uploading L1.str



chain nodes :
6 7 8 9 10 11 21 22 23 24 33 34 36 37 38 39 40 41 43 44 45 49

ring nodes :

1 2 3 4 5

ring/chain nodes :

12 13

chain bonds :

1-6 3-33 4-49 5-34 6-7 7-8 8-9 9-10 10-11 22-23 36-43 36-44 37-45 38-39

39-40 39-41

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 1-6 2-3 3-4 3-33 4-5 4-49 5-34 6-7 7-8 8-9 9-10 10-11 36-43 36-44 37-45 38-39 39-40 39-41

exact bonds :

22-23

G1:[*1-*2],[*3-*4]

G2:[*5],[*6],[*7]

G3:H,Cb,Ak

G4:[*8],[*9],[*10]

Hydrogen count :

3:>= minimum 0

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS

10:CLASS

11:CLASS 12:CLASS 13:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 33:CLASS

34:CLASS 36:CLASS

37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 43:CLASS 44:CLASS 45:CLASS

49:CLASS

Structure search history

=> d stat query L4
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L3 12 SEA FILE=REGISTRY SSS FUL L1

L4 5 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L3

Structure search results

=> d L4 1-5 ibib ed abs hitstr

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:22645 HCAPLUS Full-text

DOCUMENT NUMBER: 146:307704

TITLE: Rhenium(V) oxocomplexes with novel pyrazolyl-based N4- and N3S-donor chelators

AUTHOR(S): Moura, Carolina; Vitor, Rute F.; Maria, Leonor; Paulo, Antonio; Santos, Isabel C.; Santos, Isabel

CORPORATE SOURCE: Departamento de Quimica, ITN, Sacavem, 2686-953, Port.

SOURCE: Dalton Transactions (2006), (47), 5630-5640

CODEN: DTARAF; ISSN: 1477-9226

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:307704

ED Entered STN: 08 Jan 2007

AB The novel pyrazolyl-based ligands 3,5-Me₂pz(CH₂)₂NH(CH₂)₂NH(CH₂)₂NH₂ (1) and pz*(CH₂)₂NH-Gly-CH₂Strit (pz* = pz (8), 3,5-Me₂pz (9), 4-(EtOOC)CH₂-3,5-Me₂pz (10)) were synthesized, and their suitability to stabilize Re(V) oxocomplexes was evaluated using different starting materials, (NBu₄)[ReOCl₄], [ReOCl₃(PPh₃)₂] and trans-[ReO₂(py)₄]Cl. Compound 1 reacts with trans-[ReO₂(py)₄]Cl yielding the cationic compound [ReO(OMe){3,5-Me₂pz(CH₂)₂NH(CH₂)₂NH(CH₂)₂NH₂}](BPh₄) (11) in a low isolated yield. In contrast, the neutral complexes [ReO{pz*(CH₂)₂NH-Gly-CH₂S}] (pz* = pz (12), 3,5-Me₂pz (13), 4-(EtOOCCH₂)-3,5-Me₂pz (14)) were synthesized almost quant. by reacting [ReOCl₃(PPh₃)₂] or (NBu₄)[ReOCl₄] with the trityl-protected chelators 8-10. The x-ray diffraction anal. of 11 and 13 confirmed the tetradentate coordination mode of the resp. ancillary ligands. In 11 the monoanionic chelator coordinates to the metal through four N atoms, while in 13 the chelator is trianionic, coordinating to the metal through three nitrogens and one S atom. Solution NMR studies of 12-14, including two-dimensional NMR techniques (1H COSY and 1H/13C HSQC), confirmed that the N3S coordination mode of the chelators is retained in solution. Unlike 11, complexes 12-14 may be considered relevant in the development of radiopharmaceuticals, as further corroborated by the synthesis of the congener [99mTcO{pz(CH₂)₂NH-Gly-CH₂S}] (12a). This radioactive compound was obtained from 99mTcO₄⁻ in aqueous medium, in almost quant. yield and with high specific activity and radiochem. purity.


IT 927883-71-4F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction with oxorhenate chloro complex)

RN 927883-71-4 HCAPLUS

CN 1H-Pyrazole-4-acetic acid, 3,5-dimethyl-1-[2-[[2-[[2-[(triphenylmethyl)thio]acetyl]amino]acetyl]amino]ethyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:1049014 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:168330
 TITLE: Rhenium(I)- and technetium(I) tricarbonyl complexes anchored by bifunctional pyrazole-diamine and pyrazole-dithioether chelators
 AUTHOR(S): Vitor, Rute F.; Alves, Susana; Correia, J. D. G.; Paulo, Antonio; Santos, Isabel
 CORPORATE SOURCE: ITN, Estrada Nacional, Departamento de Quimica, Sacavem Codex, 2686-953, Port.
 SOURCE: Journal of Organometallic Chemistry (2004), 689(25), 4764-4774
 CODEN: JORCAI; ISSN: 0022-328X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:168330

ED Entered STN: 08 Dec 2004


AB The novel pyrazolyl containing ligands 4-(HOOC)pz(CH₂)₂NH(CH₂)₂NH₂ (L1) and 4-(HOOCCH₂)-3,5-Me₂pz(CH₂)₂NH(CH₂)₂NH₂ (L2), and 3,5-Me₂pz(CH₂)₂S(CH₂)₂SCH₂CH₃ (L3), 3,5-Me₂pz(CH₂)₂S(CH₂)₂SCH₂COOEt (L4) and 3,5-Me₂pz(CH₂)₂S(CH₂)₂SCH₂COOH (L5) were synthesized, and their ability to stabilize complexes with the fac-[M(CO)₃]⁺ (M = Re, ^{99m}Tc) moiety was evaluated. Reactions of L1-L5 with (NEt₄)₂[Re(CO)₃Br₃] and/or [Re(CO)₅Br] afforded complexes fac-[Re(CO)₃(κ³-L)] (L = L1-L5 (1-5)), which contain the pyrazolyl ancillary ligands coordinated in a tridentate fashion. Complexes 1-5 were characterized by the common anal. techniques, which included single crystal x-ray diffraction anal. in the case of 4. The structural anal. of 4 confirmed the tridentate coordination mode of the pyrazole-dithioether ligand, which is facially coordinated to the Re(I) center through the N from the pyrazole ring and the two thioether S atoms, without involvement of the terminal ester functional group. The distorted octahedral coordination environment around the metal is completed by the three facial carbonyl ligands. The radioactive congeners of complexes 1, 3 and 4, fac-[^{99m}Tc(CO)₃(κ³-L)]⁺ (L = L1 (1a), L3 (3a), L4 (4a)), were prepared by reacting the precursor fac-[^{99m}Tc(CO)₃(H₂O)₃]⁺ with the corresponding ligands, and their identity confirmed by HPLC comparison with the Re surrogates. Complexes 1a and 3a were challenged in the presence of a large excess of histidine or cysteine, to evaluate their in vitro stability. Only a negligible displacement was observed, indicating that pyrazole-diamine and pyrazole-dithioether chelators provide a high kinetic inertness and/or stability to organometallic complexes with the fac-[^{99m}Tc(CO)₃]⁺ moiety.

IT 827596-91-8F


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and complexation with rhenium)

RN 827596-91-8 HCAPLUS

CN 1H-Pyrazole-4-acetic acid, 1-[2-[(2-aminoethyl)amino]ethyl]-3,5-dimethyl-, ethyl ester (CA INDEX NAME)



IT 827596-90-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and complexation with rhenium and technetium)
 RN 827596-90-7 HCAPLUS
 CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[(2-aminoethyl)amino]ethyl]-, ethyl
 ester (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:902222 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 141:387794
 TITLE: Preparation of bifunctional pyrazole-containing
 tridentate ligands for rhenium and technetium
 tricarbonyl complexes
 INVENTOR(S): Santos, Isabel R.; Galamba Correia, Joao D.; Rocha
 Paulo, Antonio M.; Alves, Susana; Vitor, Rute
 PATENT ASSIGNEE(S): Mallinckrodt Inc., USA
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091669	A1	20041028	WO 2004-US11685	20040415
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1529537	A1	20050511	EP 2003-78217	20031010
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
AU 2004229568	A1	20041028	AU 2004-229568	20040415
CA 2522326	A1	20041028	CA 2004-2522326	20040415
EP 1644050	A1	20060412	EP 2004-759566	20040415

10/551,292


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

CN 1774268	A	20060517	CN 2004-80010214	20040415
JP 2007525452	T	20070906	JP 2006-510091	20040415
US 20060198785	A1	20060907	US 2005-551292	20050928
IN 2005CN02650	A	20070525	IN 2005-CN2650	20051014
NO 2005005334	A	20051111	NO 2005-5334	20051111
PRIORITY APPLN. INFO.:			EP 2003-76106	A 20030415
			EP 2003-78217	A 20031010
			WO 2004-US11685	W 20040415

OTHER SOURCE(S): MARPAT 141:387794

ED Entered STN: 28 Oct 2004

GI



AB The present invention relates to a chelating agent I [$m = 0, 1$; $X = NR_4, S$; $Y = SR_5, P(R_5)_2$; $R_1, R_3 =$ independently H, alkyl, aryl; $R_2 = H, CO_2H, NHR_6, (CH_2)_nCO_2R_6$; $R_4 = H, alkyl, aryl, (CH_2)_nCO_2R_6, (CH_2)_nOR_6$; $R_5 = H, alkyl, aryl, (CH_2)_nCO_2R_6, (CH_2)_nOR_6, R_6 = H, alkyl, aryl$; $n = 1-10$; when $R_1 = R_3 = CH_3, R_2, R_4, R_5$ are not all = H]. The invention further relates to a method and kit for the preparation of radiolabeled biomols. while using the chelating agent. Thus, pyrazole II ($R = CO_2H$) was prepared by cyclocondensation of $(OHC)_2CHCO_2Et$ with $H_2NNHCH_2CH_2OH$, followed by tosylation and substitution with ethylenediamine and saponification Prepared compds. II ($R = H, CO_2H$) underwent complexation with rhenium and technetium-99 to give the corresponding tricarbonyl complexes.


IT 782501-75-1F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bifunctional pyrazole-containing tridentate ligands for rhenium and technetium tricarbonyl complexes)

RN 782501-75-1 HCAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[(2-aminoethyl)amino]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

10/551,292

ACCESSION NUMBER: 1990:591969 HCAPLUS Full-text
DOCUMENT NUMBER: 113:191969
ORIGINAL REFERENCE NO.: 113:32513a,32516a
TITLE: Renin inhibitory peptides containing
(4S)-amino-5-cyclohexyl-(3S)-hydroxypentanoic acid
INVENTOR(S): Smith, Stephen Allan; Ham, Peter; Nash, David John
PATENT ASSIGNEE(S): Beecham Group PLC, UK
SOURCE: Eur. Pat. Appl., 91 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 350163	A2	19900110	EP 1989-305691	19890606
EP 350163	A3	19901122		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8902794	A	19891210	DK 1989-2794	19890607
AU 8936121	A	19891214	AU 1989-36121	19890607
ZA 8904301	A	19900530	ZA 1989-4301	19890607
JP 02036169	A	19900206	JP 1989-144298	19890608
PRIORITY APPLN. INFO.:			GB 1988-13671	A 19880609
			GB 1988-29065	A 19881213
			GB 1989-6262	A 19890318

OTHER SOURCE(S): MARPAT 113:191969

ED Entered STN: 23 Nov 1990

GI For diagram(s), see printed CA Issue.

AB The title peptides [I; Z1Z2Z3 = atoms to complete a 5-membered nonarom. heterocyclic ring; E = absent, (CH2)n, CH(CH2)n-1; n = 1-4; A = CONH, NHCO, CO2, CH2, S(O)r; r, p = 0-2; q = 0,1; R1 = (un)substituted (hetero)arylmethyl; R2 = CHR8R9; R8 = H, Me and R9 = C1-6 alkyl, C3-8 cycloalkyl, (un)substituted (hetero)aryl; R9 = NH2, C2-7 alkanoylamino, 2-oxopyrrolidinyl, etc.; R3 = alkyl, cycloalkylmethyl; R4 = (cyclo)alkyl; R5 = H, alkyl; or R5 = OH when A = CH2; R6,R7 = H, substituent], useful for the treatment of hypertension, are prepared Thus, N-(2,3-dihydrobenzofuran-2-carbonyl)-(S)-phenylalanyl-(S)-leucine was condensed with (4S)-amino-5-cyclohexyl-(3S)-hydroxypentanoic acid isobutylamide (ACHPAA) in the presence of hydroxybenzotriazole and DCC in THF at room temperature overnight to give Q-Phe-Leu-ACHPAA (II; Q = 2,3-dihydrobenzofuran-2-carbonyl). II [Q = (6-aminomethyl-2,3-dihydro-1,1-dioxobenzothiophen-3-ylacetyl] in vitro inhibited human renin with an IC50 of 0.8 + 10-8M. A total of 75 I were prepared

IT 130106-44-4F 130106-45-5F 130120-64-8F

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of, as intermediate for renin-inhibitory peptide)

RN 130106-44-4 HCAPLUS

CN L-threo-Pentonamide, 4-[[2-amino-3-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1H-pyrazol-1-yl]-1-oxopropyl]amino]-5-cyclohexyl-2,4,5-trideoxy-N-(2-methylpropyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/551,292



RN 130106-45-5 HCAPLUS


CN L-threo-Pentonamide, 5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[(2,3-dihydro-1,1-dioxidobenzo[b]thien-3-yl)acetyl]-L-phenylalanyl]-3-[4-[(1,1-dimethylethoxy)carbonyl]amino]-1H-pyrazol-1-yl]-L-alanyl]amino]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 130120-64-8 HCAPLUS

CN L-threo-Pentonamide, 5-cyclohexyl-2,4,5-trideoxy-4-[[3-[4-[(1,1-dimethylethoxy)carbonyl]amino]-1H-pyrazol-1-yl]-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]propyl]amino]-N-(2-methylpropyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 130105-06-SP

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)
(preparation of, as renin inhibitor)

RN 130105-06-5 HCAPLUS

CN L-threo-Pentonamide, 4-[[3-(4-amino-1H-pyrazol-1-yl)-N-[N-[(2,3-dihydro-1,1-dioxidobenzo[b]thien-3-yl)acetyl]-L-phenylalanyl]-L-alanyl]amino]-5-cyclohexyl-2,4,5-trideoxy-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1985:6272 HCAPLUS Full-text

DOCUMENT NUMBER: 102:6272

ORIGINAL REFERENCE NO.: 102:1139a,1142a

TITLE: New aspects of the 1,3-dipolar cycloaddition of
thiazolium N-imines with dimethyl
acetylenedicarboxylate (DMAD)

AUTHOR(S): Hirano, Hiroshi; Sugiyama, Kazuaki; Yamashita, Mayumi;
Ishida, Toshimasa; Doi, Mitsunobu; Inoue, Masatoshi

CORPORATE SOURCE: Osaka Coll. Pharm., Matsubara, 580, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1984), 32(6),
2446-9

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 12 Jan 1985

AB 4-Methylthiazolium N-imine reacted with DMAD in MeOH to give 3 products, di-Me [2-[3,4-bis(methoxycarbonyl)-1-pyrazolyl]propenylthio]fumarate, di-Me 2,3-bis[2-[3,4-bis(methoxycarbonyl)-1-pyrazolyl]propenylthio]succinate, and 3-methyl-6-methoxycarbonyl-8-oxidothiazolo[3,2-b]pyridazinium (I). The structure of I was established by x-ray anal. and IR spectral data. In a similar reaction with 4,5-dimethylthiazolium N-imine, 2,3-dimethyl-6,7-bis(methoxycarbonyl)-7,7a-dihydro-4H-thiazolo[3,2-b]pyrazole was isolated, and this compound, when heated in EtOH, underwent ring expansion into an analog of I.


IT 93623-91-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 93623-91-7 HCAPLUS

CN 1H-Pyrazole-3,4-dicarboxylic acid,
1,1'-[[1,2-bis(methoxycarbonyl)-1,2-ethanediyl]bis[thio(1-methyl-2,1-ethenediyl)]]bis-, tetramethyl ester (9CI) (CA INDEX NAME)

10/551,292



Inventor search history

=> d his L23

(FILE 'HCAPLUS' ENTERED AT 10:19:08 ON 16 DEC 2008)

L23 14 S L20 OR L22

=> d que L23

L5	483	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	SANTOS I?/AU
L6	527	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	CORREIA J?/AU
L7	91	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	PAULO A?/AU
L8	324	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	ALVES S?/AU
L9	20	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	VITOR R?/AU
L10	2	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L5 AND L6 AND L7 AND L8 AND L9
L11	56	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L5 AND (L6 OR L7 OR L8 OR L9)
L12	12	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L6 AND (L7 OR L8 OR L9)
L13	8	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L7 AND (L8 OR L9)
L14	3	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L8 AND L9
L15	1366	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	(L5 OR L6 OR L7 OR L8 OR L9)
L16	3	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L15 AND MALLINCKRODT?/ CO,CS,PA,SO
L17	57	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	(L11 OR L12 OR L13 OR L14)
L18	32	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L17 AND PYRAZOL?
L19	28	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L17 AND (TRICARBON? OR TRIDENT?)
L20	5	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L10 OR L16
L22	11	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L18 AND L19
L23	14	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L20 OR L22

=> d que L24

L5	483	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	SANTOS I?/AU
L6	527	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	CORREIA J?/AU
L7	91	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	PAULO A?/AU
L8	324	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	ALVES S?/AU
L9	20	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	VITOR R?/AU
L10	2	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L5 AND L6 AND L7 AND L8 AND L9
L24	0	SEA	L10				

=> d his L24

(FILE 'MEDLINE, BIOSIS, EMBASE, DRUGU' ENTERED AT 10:29:22 ON 16 DEC 2008)

L24 0 S L10

=> d his L25

(FILE 'MEDLINE, BIOSIS, EMBASE, DRUGU' ENTERED AT 10:29:22 ON 16 DEC 2008)

L25 16 S L23

=> d que L25

L5	483	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	SANTOS I?/AU
L6	527	SEA	FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	CORREIA J?/AU

10/551,292

L7	91	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	PAULO A?/AU
L8	324	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	ALVES S?/AU
L9	20	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	VITOR R?/AU
L10	2	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L5 AND L6 AND L7 AND L8 AND L9
L11	56	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L5 AND (L6 OR L7 OR L8 OR L9)
L12	12	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L6 AND (L7 OR L8 OR L9)
L13	8	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L7 AND (L8 OR L9)
L14	3	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L8 AND L9
L15	1366	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	(L5 OR L6 OR L7 OR L8 OR L9)
L16	3	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L15 AND MALLINCKRODT?/ CO,CS,PA,SO
L17	57	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	(L11 OR L12 OR L13 OR L14)
L18	32	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L17 AND PYRAZOL?
L19	28	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L17 AND (TRICARBON? OR TRIDENT?)
L20	5	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L10 OR L16
L22	11	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L18 AND L19
L23	14	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L20 OR L22
L25	16	SEA L23				

=> dup rem L23 L25

FILE 'HCAPLUS' ENTERED AT 11:06:27 ON 16 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:06:27 ON 16 DEC 2008

FILE 'BIOSIS' ENTERED AT 11:06:27 ON 16 DEC 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:06:27 ON 16 DEC 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'DRUGU' ENTERED AT 11:06:27 ON 16 DEC 2008

COPYRIGHT (C) 2008 THOMSON REUTERS

PROCESSING COMPLETED FOR L23

PROCESSING COMPLETED FOR L25

L34 15 DUP REM L23 L25 (15 DUPLICATES REMOVED)
 ANSWERS '1-14' FROM FILE HCAPLUS
 ANSWER '15' FROM FILE EMBASE

Inventor search results

=> d L34 1-15 ibib ab

L34 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2008:521195 HCAPLUS Full-text
 TITLE: Pyrazolyl-diamine ligands that bear anthracenyl moieties and their rhenium(I) tricarbonyl complexes: synthesis, characterisation and DNA-binding properties
 AUTHOR(S): Vitor, Rute F.; Correia, Isabel; Videira, Margarida; Marques, Fernanda; Paulo, Antonio; Pessoa, Joao Costa; Viola, Giampietro; Martins, Gabriel G.; Santos, Isabel
 CORPORATE SOURCE: Departamento de Quimica, ITN, Sacavem, 2686-953, Port.
 SOURCE: ChemBioChem (2008), 9(1), 131-142
 CODEN: CBCHFX; ISSN: 1439-4227
 PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Two novel families of pyrazolyl-diamine ligands that bear an anthracen-9-yl group as a DNA-binding fragment, pz*(CH₂)₂NH(CH₂)₂NHCH₂-9-anthryl (pz* = pz (L1), 3,5-Me₂pz (L2)) and pz*(CH₂)₂NH(CH₂)₂NH₂ (pz* = 4-(9-anthrylmethyl)pz (L3), 3,5-Me₂-4-(9-anthrylmethyl)pz (L4)), have been prepared and fully characterised. In the case of L2-L4, the evaluation of their coordination capability towards the fac-[Re(CO)₃]⁺ core led to the synthesis of the organometallic complexes fac-[Re(CO)₃{3,5-Me₂pz(CH₂)₂NH(CH₂)₂NHCH₂-9-anthryl}]Br (7) and fac-[Re(CO)₃{4-(9-anthrylmethyl)pz*(CH₂)₂NH(CH₂)₂NH₂}]Br (pz* = pz (8), 3,5-Me₂pz (9)). The interaction of the novel pyrazole-diamine ligands and the rhenium(I) complexes with calf thymus (CT) DNA has been investigated with a variety of spectroscopic techniques (UV-visible, fluorescence, CD (CD) and linear dichroism (LD)). All of the evaluated compds. have a moderate affinity to CT DNA (3.46 + 10³ < K_b < 1.95 + 10⁴), but the binding mode depends on the position of the chromophore in the framework of the pyrazolyl-diamine ligands. LD measurements have shown that L1 and L2 act as DNA intercalators, but complex 7 intercalates only partially. By contrast, the compds. with the anthracenyl group at the 4-position of the azolyl ring (L3, L4 and 9) do not intercalate, and behave more like DNA groove binders. Fluorescence microscopy studies have demonstrated that complexes 7 and 9 can target the nucleus of murine B16-F1 melanoma cells, and appear to be promising platforms for the further design of radiopharmaceuticals for targeted radiotherapy.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2007:749128 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:334888
 TITLE: Rhenium and technetium tricarbonyl complexes anchored by pyrazole-based tripods: novel lead structures for the design of myocardial imaging agents
 AUTHOR(S): Maria, Leonor; Cunha, Susana; Videira, Margarida; Gano, Lurdes; Paulo, Antonio; Santos, Isabel C.; Santos, Isabel
 CORPORATE SOURCE: Departamento de Quimica, ITN, Sacavem, 2686-953, Port.
 SOURCE: Dalton Transactions (2007), (28), 3010-3019
 CODEN: DTARAF; ISSN: 1477-9226
 PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 147:334888

AB This report describes the synthesis and biol. evaluation of cationic ^{99m}Tc -tricarbonyl complexes anchored by ether-containing tris(pyrazolyl)methane or bis(pyrazolyl)ethanamine ligands to be applied in the design of radiopharmaceuticals for myocardial imaging: fac- $[\text{fac-}^{99m}\text{Tc}(\text{CO})_3\{\text{RC}(\text{pz})_3\}]^+$ (R = H (1a), MeOCH_2 (2a), EtOCH_2 (3a), PrOCH_2 (4a)) and fac- $[\text{fac-}^{99m}\text{Tc}(\text{CO})_3\{\text{RNHCH}_2\text{CH}(\text{pz})_2\}]^+$ (R = H (5a), $\text{MeO}(\text{CH}_2)_2$ (6a)) (pz = pyrazolyl). At the no carrier added level, complexes 1a-6a were obtained in high radiochem. yield (> 98%) by reaction of fac- $[\text{fac-}^{99m}\text{Tc}(\text{CO})_3(\text{H}_2\text{O})_3]^+$ with the corresponding tripod chelator in aqueous medium. All these complexes display a high in vitro and in vivo stability, except 6a which metabolizes in vivo yielding fac- $[\text{fac-}^{99m}\text{Tc}(\text{CO})_3\{\text{HO}(\text{CH}_2)_2\text{NHCH}_2\text{CH}(\text{pz})_2\}]^+$ (7a). Biol. studies in mice showed that among the radiotracers evaluated 3a, anchored by a tris(pyrazolyl)methane chelator bearing an Et Me ether substituent, has the highest heart uptake ($3.6 \pm 0.5\%$ ID g⁻¹ at 60 min p.i.). Complex 3a presents also the best heart : blood, heart : liver and heart : lung ratios, appearing as the most promising as a potential myocardial imaging agent. The chemical identity of 1a-7a was ascertained by HPLC comparison with the previously reported fac- $[\text{Re}(\text{CO})_3\{\text{HC}(\text{pz})_3\}]\text{Br}$ (1) and with the novel fac- $[\text{Re}(\text{CO})_3\{\text{RC}(\text{pz})_3\}]\text{Br}$ (R = MeOCH_2 (2), EtOCH_2 (3), PrOCH_2 (4)) and fac- $[\text{Re}(\text{CO})_3\{\text{RNHCH}_2\text{CH}(\text{pz})_2\}]\text{Br}$ (R = H (5), $\text{MeO}(\text{CH}_2)_2$ (6) $\text{HO}(\text{CH}_2)_2$ (7)). The novel Re(I) tricarbonyl complexes 2-7 were characterized by the common anal. techniques, including single crystal x-ray diffraction anal. The solid state structure confirmed the presence of facial and tridentate ($\kappa^3\text{-N}_3$) anchor ligands. Solution NMR studies also showed that this $\kappa^3\text{-N}_3$ coordination mode is retained in solution for all complexes (2-7).

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2007:605111 HCAPLUS Full-text

DOCUMENT NUMBER: 147:229603

TITLE: A new bisphosphonate-containing $^{99m}\text{Tc}(\text{I})$ tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation

AUTHOR(S): Palma, Elisa; Oliveira, Bruno L.; Correia, Joao D. G.; Gano, Lurdes; Maria, Leonor; Santos, Isabel C.; Santos, Isabel

CORPORATE SOURCE: Departamento de Quimica, ITN, Sacavem Codex, 2686-953, Port.

SOURCE: JBIC, Journal of Biological Inorganic Chemistry (2007), 12(5), 667-679
 CODEN: JJBCFA; ISSN: 0949-8257

PUBLISHER: Springer GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Aiming to develop new bone-seeking radiotracers based on the organometallic core fac- $[\text{fac-}^{99m}\text{Tc}(\text{CO})_3]^+$ with improved radiochem. and biol. properties, we have prepared new conjugates with phosphonate pendant groups. The conjugates comprise a chelating unit for metal coordination, which corresponds to a pyrazolyl-containing backbone (pz) with a N,N,N donor-atom set, and a pendant di-Et phosphonate (pz-MPOEt), phosphonic acid (pz-MPOH) or a bisphosphonic acid (pz-BPOH) group for bone targeting. Reactions of the conjugates with the precursor $[\text{fac-}^{99m}\text{Tc}(\text{H}_2\text{O})_3(\text{CO})_3]^+$ yielded (more than 95%) the single and well-defined radioactive species $[\text{fac-}^{99m}\text{Tc}(\text{CO})_3(\kappa^3\text{-pz-MPOEt})]^+$ (1a), $[\text{fac-}^{99m}\text{Tc}(\text{CO})_3(\kappa^3\text{-pz-MPOH})]^+$ (2a) and $[\text{fac-}^{99m}\text{Tc}(\text{CO})_3(\kappa^3\text{-pz-BPOH})]^+$ (3a), which were characterized by

reversed-phase high-performance liquid chromatog. . The corresponding Re surrogates (1-3), characterized by the usual anal. techniques, including X-ray diffraction anal. in the case of 1, allowed for macroscopic identification of the radioactive conjugates. These radioactive complexes revealed high stability both in vitro (phosphate-buffered saline solution and human plasma) and in vivo, without any measurable decomposition. Biodistribution studies of the complexes in mice indicated a fast rate of blood clearance and high rate of total radioactivity excretion, occurring primarily through the renal-urinary pathway in the case of complex 3a. Despite presenting moderate bone uptake ($3.04 \pm 0.47\%$ injected dose per g of organ, 4 h after injection), the high stability presented by 3a and its adequate in vivo pharmacokinetics encourages the search for new ligands with the same chelating unit and different bisphosphonic acid pendant arms.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2006:711846 HCAPLUS Full-text

DOCUMENT NUMBER: 146:223509

TITLE: Pyrazolyl conjugates of bombesin: A new tridentate ligand framework for the stabilization of fac-[M(CO)₃]+ moiety

AUTHOR(S): Alves, Susana; Correia, Joao D. G.; Santos, Isabel; Veerendra, Bhadrasetty; Sieckman, Gary L.; Hoffman, Timothy J.; Rold, Tammy L.; Figueroa, Said Daibes; Retzlöff, Lauren; McCrate, Joseph; Prasanphanich, Adam; Smith, Charles J.

CORPORATE SOURCE: Department of Radiology, University of Missouri-Columbia School of Medicine, Columbia, MO, 65211, USA

SOURCE: Nuclear Medicine and Biology (2006), 33(5), 625-634
CODEN: NMBIEO; ISSN: 0969-8051

PUBLISHER: Elsevier Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We have described the synthesis of tridentate pyrazolyl ligand frameworks for coordination to the fac-[*M(CO)₃]+ metal fragment (*M = ¹⁸⁶/188Re or ^{99m}Tc). These ligands impart a degree of kinetic inertness on the metal center, warranting their study in biol. systems. We herein report in vitro/in vivo radiolabeling investigations of a new series of pyrazolyl bombesin (BBN) conjugates radiolabeled via the Isolink kit. These new conjugates are based on the general structure [^{99m}Tc-pyrazolyl-X-BBN[7-14]NH₂], where X = β-alanine, serylserylserine or glycylglycylglycine. The pyrazolyl ligand is a tridentate ligand framework that coordinates the metal center through nitrogen donor atoms. The results of these investigations demonstrate the ability of these new conjugates to specifically target the gastrin-releasing peptide receptor subtype 2, which is overexpressed on human prostate PC-3 cancerous tissues. Therefore, these studies suggest the tridentate pyrazolyl ligand framework to be an ideal candidate for the design and development of low-valent ^{99m}Tc-based diagnostic radiopharmaceuticals based on BBN or other targeting vectors.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2006:166490 HCAPLUS Full-text

DOCUMENT NUMBER: 145:450851

TITLE: Radiopharmaceuticals for targeted radiotherapy

AUTHOR(S): Marques, Fernanda; Paulo, Antonio; Campello, Maria Paula; Lacerda, Sara; Vitor, Rute Filipe

CORPORATE SOURCE: ; Gano, Lurdes; Delgado, Rita; Santos, Isabel
 Departamento de Quimica, Instituto Tecnológico e
 Nuclear, Sacavem, 2686-953, Port.
 SOURCE: Radiation Protection Dosimetry (2005), 116(1-4),
 601-604
 CODEN: RPDODE; ISSN: 0144-8420
 PUBLISHER: Oxford University Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB This work intends to find specific radiopharmaceuticals for cancer therapy
 based on beta (153Sm and 166Ho) or Auger (99Tcm) emitter radionuclides, using
 cyclic and acyclic polyamines as bifunctional chelators. These chelators are
 designed to allow the binding of a tumor seeking biomol. and/or a DNA
 intercalates. The cyclic amines, such as 1,4,7,10-tetraazacyclododecane-
 1,4,7,10-tetraacetic acid, 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-
 tetraacetic acid and 1,4,7,10-tetraazacyclotridecane-1,4,7,10-tetraacetic
 acid, were radiolabeled with 153Sm and 166Ho. The radiochem. and biol.
 behavior of the resulting complexes were evaluated in order to assess their
 potential as building blocks for the attachment of selected biomols., with the
 aim of further applying them for the development of specific therapeutic
 radiopharmaceuticals. Novel pyrazolyldiamines, bearing a DNA intercalating
 anthracenyl fragment, were also explored to synthesize radioactive complexes
 with the fac-[99Tcm(CO)]3+ moiety. The identity of these 99Tcm tricarbonyl
 complexes was confirmed by high-performance liquid chromatog. comparison with
 rhenium congeners fully characterized. By including a DNA intercalator into
 the chelator framework, we expect to induce more efficient and selective
 damage to the DNA of cancer cells by the action of the short-range Auger
 electrons emitted by 99Tcm.
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2005:205084 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:406796
 TITLE: Pyrazolyl Derivatives as Bifunctional
 Chelators for Labeling Tumor-Seeking Peptides with the
 fac-[M(CO)3]+ Moiety (M = 99mTc, Re): Synthesis,
 Characterization, and Biological Behavior
 AUTHOR(S): Alves, Susana; Paulo, Antonio;
 Correia, Joao D. G.; Gano, Lurdes; Smith,
 Charles J.; Hoffman, Timothy J.; Santos,
 Isabel
 CORPORATE SOURCE: Departamento de Quimica, ITN, Sacavem, 2686-953, Port.
 SOURCE: Bioconjugate Chemistry (2005), 16(2), 438-449
 CODEN: BCCHE; ISSN: 1043-1802
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Radiolabeling of biol. active mols. with the [99mTc(CO)3]+ unit has been of
 primary interest in recent years. With this in mind, we herein report sym.
 (L1) and asym. (L2-L5) pyrazolyl-containing chelators that have been evaluated
 in radiochem. reactions with the synthon [99mTc(H2O)3(CO)3]+ (1a). These
 reactions yielded the radioactive building blocks [99mTc(CO)3(k3-L)]+ (L = L1-
 L5, 2a-6a), which were identified by RP-HPLC. The corresponding Re surrogates
 (2-6) allowed for macroscopic identification of the radiochem. conjugates.
 Complexes 2a-6a, with log Po/w values ranging from -2.35 to 0.87, were
 obtained in yields of ≥90% using ligand concns. in the 10⁻⁵-10⁻⁴ M range.
 Challenge studies with cysteine and histidine revealed high stability for all
 of these radioactive complexes, and biodistribution studies in mice indicated
 a fast rate of blood clearance and high rate of total radioactivity excretion,

occurring primarily through the renal-urinary pathway. Based on the framework of the asym. chelators, the novel bifunctional ligands 3,5-Me2-pz(CH2)2N((CH2)3COOH)(CH2)2NH2 (L6) and pz(CH2)2N((CH2)3COOH)(CH2)2NH2 (L7) have been synthesized and their coordination chemical toward (Net4)2[ReBr3(CO)3] (1) has been explored. The resulting complexes, fac-[Re(CO)3(κ^3 -L)]Br (L6 (7), L7 (8)), contain tridentate ancillary ligands that are coordinated to the metal center through the pyrazolyl and amine nitrogen atoms, as observed for the other related building blocks. L6 and L7 were coupled to a glycylglycine Et ester dipeptide, and the resulting functionalized ligands were used to prepare the model complexes fac-[Re(CO)3(κ^3 -3,5-Me2-pz(CH2)2N(glygly)(CH2)2NH2)]+ (9/9a) and fac-[Re(CO)3(κ^3 -pz(CH2)2N(CH2)3(glygly)(CH2)2NH2)]+ (10/10a) (M = Re, 99mTc). These small conjugates have been fully characterized and are reported herein. On the basis of the in vitro/in vivo behavior of the model complexes (2a-6a, 9a, 10a), we chose to evaluate the in vitro/in vivo biol. behavior of a new tumor-seeking Bombesin pyrazolyl conjugate, [(L6)-G-G-G-Q-W-A-V-G-H-L-M-NH2], that has been labeled with the [99mTc(CO)3]+ metal fragment. Stability, in vitro cell binding assays, and pharmacokinetics studies in normal mice are reported herein.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:639917 HCAPLUS Full-text

DOCUMENT NUMBER: 148:599283

TITLE: Tricarbonyl complexes with tridentate chelators for myocardium imaging

INVENTOR(S): Dos Santos, Isabel da Graca Rego; Paulo, Antonio
Manuel Rocha

PATENT ASSIGNEE(S): Mallinckrodt Inc., USA

SOURCE: PCT Int. Appl., 50pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008061792	A2	20080529	WO 2007-EP10216	20071123
WO 2008061792	A3	20080807		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: GB 2006-23482 A 20061124

OTHER SOURCE(S): CASREACT 148:599283; MARPAT 148:599283

AB Chelators tris(pyrazolyl)methanes (I) and bis(pyrazolyl)amines (II) and (III) (each of R1, R2, R3 and R4 is independently H, linear or branched, (un)saturated C1-9 alkyl; (un)saturated carboxylic group; (un)saturated heterocyclic of heteroaliph. group with 1 or more selected from O, N and S) and Re and 99mTc tricarbonyl complexes of these ligands are reported for use

in myocardial imaging. For example O-methyl-1,1,1-tris(pyrazol-1-yl)ethanol was prepared in a multistep process starting from 2,2,2-tris(pyrazol-1-yl)ethanol and its Re(CO)₃ and ^{99m}Tc(CO)₃ complexes were prepared. The biodistribution of the Tc complexes was determined.

L34 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:706224 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:108440
 TITLE: Tripodal ligands with the coordinating motifs
 κ²-BH₂ or κ³-BH₃ relevant for biomedical
 applications of organometallic complexes
 INVENTOR(S): Santos, Isabel Rego; Paulo, Antonio
 Manuel Rocha
 PATENT ASSIGNEE(S): Mallinckrodt Inc., USA
 SOURCE: PCT Int. Appl., 34pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2007073472	A2	20070628	WO 2006-US47877	20061215
WO 2007073472	A3	20070907		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
CA 2634704	A1	20070628	CA 2006-2634704	20061215
EP 1981894	A2	20081022	EP 2006-848716	20061215
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
KR 2008080330	A	20080903	KR 2008-715270	20080623
PRIORITY APPLN. INFO.:			EP 2005-77977	A 20051223
			EP 2006-75127	A 20060119
			WO 2006-US47877	W 20061215

OTHER SOURCE(S): MARPAT 147:108440

AB The present invention relates to a compound for use as a chelator in the radioactive labeling of biomols. with metal tricarbonyl complexes, which compound has the general formula M[BH₂RR₁] (M = a monovalent cation, such as Li, Na, K, Tl, Rb, Cs or an alkylammonium; R = H, alkyl, aryl or a biomol.; R₁ = H or a pendant arm, said pendant arm optionally comprises a biomol., with the proviso that when R = H, R₁ is not H or COOH, and when R = alkyl or aryl, R₁ is not H). These Mn, Re and Tc carbonyl complexes with [BH₂RR₁]⁻ can be used in the diagnosis and/or therapy of cancer.

L34 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:722140 HCAPLUS Full-text
 DOCUMENT NUMBER: 145:347251

TITLE: Synthesis and biological evaluation of tricarboxyl Re(I) and Tc(I) complexes anchored by poly(azoly)borates: application on the design of radiopharmaceuticals for the targeting of 5-HT1A receptors

AUTHOR(S): Garcia, Raquel; Gano, Lurdes; Maria, Leonor; Paulo, Antonio; Santos, Isabel; Spies, Hartmut

CORPORATE SOURCE: Departamento de Quimica, ITN, Estrada Nacional 10, Sacavem Codex, 2686-953, Port.

SOURCE: JBIC, Journal of Biological Inorganic Chemistry (2006), 11(6), 769-782
CODEN: JJBCFA; ISSN: 0949-8257

PUBLISHER: Springer GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:347251

AB The building blocks fac-[99mTc{κ3-HB(timMe)3}(CO)3] and fac-[99mTc{κ3-R(μ-H)B(timMe)2}(CO)3] [R is H (4a), Ph (5a); timMe is 2-mercapto-1-methylimidazolyl] were obtained almost quant. by reacting fac-[99mTc(CO)3(H2O)3]+ with the corresponding scorpionate. These compds. cross the intact blood-brain barrier in mice, with significant retention in the case of 4a and 5a. Using 4a as the lead structure, the authors synthesized the functionalized complexes fac-[M{κ3-H(μ-H)B(timBu-pip)2}(CO)3] [M is Re (8), 99mTc (8a); timBu-pip is Me[4-((2-methoxyphenyl)-1-piperazinyl)butyl](2-mercapto-1-methylimidazol-5-yl)methanamide] and fac-[M{κ3-H(μ-H)B(timMe)(timBu-pip)}(CO)3] [M is Re (9), 99mTc (9a)] and evaluated their potential as radioactive probes for the targeting of brain 5-HT1A serotonergic receptors. The Re complexes exhibit excellent affinity [IC50=0.172 ± 0.003 nM (8); IC50 = 0.65 ± 0.01 nM (9)] for the 5-HT1A receptor. The radioactive congeners (99mTc) showed an initial brain uptake of 1.38 ± 0.46%ID g-1 (8a) and 0.43 ± 0.12%ID g-1 (9a), but suffer from a relatively fast washout.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:957931 HCAPLUS Full-text

DOCUMENT NUMBER: 147:202224

TITLE: Metal-based drugs for diagnosis and therapy

AUTHOR(S): Alves, Susana; Vitor, Rute; Raposinho, Paula D.; Marques, Fernanda; Correia, Joao D. G.; Paulo, Antonio; Santos, Isabel

CORPORATE SOURCE: Departamento de Quimica, Instituto Tecnologico e Nuclear, Sacavem, 2686-953, Port.

SOURCE: Metal Ions in Biology and Medicine (2006), 9, 3-8
CODEN: MIBMCT; ISSN: 1257-2535

PUBLISHER: John Libbey Eurotext

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:202224

AB The compound 3,5Me-pz(CH2)2NH(CH2)2NH2 (L1) is a very effective chelator for the fac-[M(CO)3(H2O)3]+ (M = Re (1) 99mTc (1a)) moieties, yielding the building blocks fac-[M(CO)3(κ3-L1)]+ (M = Re (2) 99mTc (2a)). The evaluation of the in vitro and in vivo behavior of 2a showed that this stable building block displays a favorable biol. profile for labeling biomols. with 99mTc, biol. active peptides. Due to its versatility, L1 was integrated through its secondary amine into a peptide with affinity for MC1 receptors (L2), and derivatized with an anthracenyl group at the C(4) position of the pyrazolyl

L34 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:902222 HCAPLUS Full-text
DOCUMENT NUMBER: 141:387794
TITLE: Preparation of bifunctional pyrazole
-containing tridentate ligands for rhenium
and technetium tricarbonyl complexes
INVENTOR(S): Santos, Isabel R.; Galamba Correia, Joao D.;
Rocha Paulo, Antonio M.; Alves, Susana;
Vitor, Rute
PATENT ASSIGNEE(S): Mallinckrodt Inc., USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

p.21

EP 2003-78217 A 20031010
WO 2004-US11685 W 20040415

OTHER SOURCE(S): MARPAT 141:387794

AB The present invention relates to a chelating agent I [$m = 0, 1$; $X = \text{NR}_4, \text{S}$; $Y = \text{SR}_5, \text{NHR}_5, \text{P}(\text{R}_5)_2$; $\text{R}_1, \text{R}_3 =$ independently $\text{H}, \text{alkyl}, \text{aryl}$; $\text{R}_2 = \text{H}, \text{CO}_2\text{H}, \text{NHR}_6, (\text{CH}_2)_n\text{CO}_2\text{R}_6$; $\text{R}_4 = \text{H}, \text{alkyl}, \text{aryl}, (\text{CH}_2)_n\text{CO}_2\text{R}_6, (\text{CH}_2)_n\text{OR}_6$; $\text{R}_5 = \text{H}, \text{alkyl}, \text{aryl}, (\text{CH}_2)_n\text{CO}_2\text{R}_6, (\text{CH}_2)_n\text{OR}_6$; $\text{R}_6 = \text{H}, \text{alkyl}, \text{aryl}$; $n = 1-10$; when $\text{R}_1 = \text{R}_3 = \text{CH}_3$, $\text{R}_2, \text{R}_4, \text{R}_5$ are not all $= \text{H}$]. The invention further relates to a method and kit for the preparation of radiolabeled biomols. while using the chelating agent. Thus, pyrazole II ($\text{R} = \text{CO}_2\text{H}$) was prepared by cyclocondensation of $(\text{OHC})_2\text{CHCO}_2\text{Et}$ with $\text{H}_2\text{NNHCH}_2\text{CH}_2\text{OH}$, followed by tosylation and substitution with ethylenediamine and saponification Prepared compds. II ($\text{R} = \text{H}, \text{CO}_2\text{H}$) underwent complexation with rhenium and technetium-99 to give the corresponding tricarbonyl complexes.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1049014 HCAPLUS Full-text

DOCUMENT NUMBER: 142:168330

TITLE: Rhenium(I)- and technetium(I) tricarbonyl complexes anchored by bifunctional pyrazole-diamine and pyrazole-dithioether chelators

AUTHOR(S): Vitor, Rute F.; Alves, Susana; Correia, J. D. G.; Paulo, Antonio; Santos, Isabel

CORPORATE SOURCE: ITN, Estrada Nacional, Departamento de Quimica, Sacavem Codex, 2686-953, Port.

SOURCE: Journal of Organometallic Chemistry (2004), 689(25), 4764-4774

CODEN: JORCAI; ISSN: 0022-328X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:168330

AB The novel pyrazolyl containing ligands 4-(HOOC)pz(CH_2) $2\text{NH}(\text{CH}_2)$ 2NH_2 (L1) and 4-(HOOCCH_2)-3,5-Me 2 pz(CH_2) $2\text{NH}(\text{CH}_2)$ 2NH_2 (L2), and 3,5-Me 2 pz(CH_2) $2\text{S}(\text{CH}_2)$ $2\text{SCH}_2\text{CH}_3$ (L3), 3,5-Me 2 pz(CH_2) $2\text{S}(\text{CH}_2)$ $2\text{SCH}_2\text{COOEt}$ (L4) and 3,5-Me 2 pz(CH_2) $2\text{S}(\text{CH}_2)$ $2\text{SCH}_2\text{COOH}$ (L5) were synthesized, and their ability to stabilize complexes with the fac-[$\text{M}(\text{CO})_3$] $^+$ ($\text{M} = \text{Re}, ^{99}\text{mTc}$) moiety was evaluated. Reactions of L1-L5 with $(\text{Net}_4)_2[\text{Re}(\text{CO})_3\text{Br}_3]$ and/or $[\text{Re}(\text{CO})_5\text{Br}]$ afforded complexes fac-[$\text{Re}(\text{CO})_3(\kappa^3\text{-L})$] ($\text{L} = \text{L1-L5}$ (1-5)), which contain the pyrazolyl ancillary ligands coordinated in a tridentate fashion. Complexes 1-5 were characterized by the common anal. techniques, which included single crystal x-ray diffraction anal. in the case of 4. The structural anal. of 4 confirmed the tridentate coordination mode of the pyrazole-dithioether ligand, which is facially coordinated to the Re(I) center through the N from the pyrazole ring and the two thioether S atoms, without involvement of the terminal ester functional group. The distorted octahedral coordination environment around the metal is completed by the three facial carbonyl ligands. The radioactive congeners of complexes 1, 3 and 4, fac-[$^{99}\text{mTc}(\text{CO})_3(\kappa^3\text{-L})$] $^+$ ($\text{L} = \text{L1}$ (1a), L3 (3a), L4 (4a)), were prepared by reacting the precursor fac-[$^{99}\text{mTc}(\text{CO})_3(\text{H}_2\text{O})_3$] $^+$ with the corresponding ligands, and their identity confirmed by HPLC comparison with the Re surrogates. Complexes 1a and 3a were challenged in the presence of a large excess of histidine or cysteine, to evaluate their in vitro stability. Only a negligible displacement was observed, indicating that pyrazole-diamine and pyrazole-dithioether chelators provide a high kinetic inertness and/or stability to organometallic complexes with the fac-[$^{99}\text{mTc}(\text{CO})_3$] $^+$ moiety.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:937047 HCAPLUS Full-text

DOCUMENT NUMBER: 138:330675

TITLE: Coordination capabilities of pyrazolyl
containing ligands towards the fac-[Re(CO)₃]⁺ moietyAUTHOR(S): Alves, Susana; Paulo, Antonio;
Correia, Joao D. G.; Domingos, Angela;
Santos, Isabel

CORPORATE SOURCE: Departamento de Quimica, ITN, Sacavem, 2686-953, Port.

SOURCE: Journal of the Chemical Society, Dalton Transactions
(2002), (24), 4714-4719

CODEN: JCSDA; ISSN: 1472-7773

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:330675

AB The coordination capabilities of the pyrazolyl containing ligands pz*(CH₂)₂NH(CH₂)₂pz*, pz*(CH₂)₂NH(CH₂)₂NH₂, pz*(CH₂)₂S(CH₂)₂pz* and pz*(CH₂)₂S(CH₂)₂NH₂ (pz* = 3,5-Me₂pz) towards the synthon (NEt₄)₂[ReBr₃(CO)₃] (1) were studied. Depending on the reaction conditions, neutral or cationic Re(I) tricarbonyl complexes were isolated: [ReBr(CO)₃(κ²-pz*(CH₂)₂NH(CH₂)₂pz*)] (2), [ReBr(CO)₃(κ²-pz*(CH₂)₂S(CH₂)₂pz*)] (3) [Re(CO)₃(κ³-pz*(CH₂)₂NH(CH₂)₂pz*)]Br (4), [Re(CO)₃(κ²-pz*(CH₂)₂S(CH₂)₂pz*)MeOH]Br (5), [Re(CO)₃(κ³-pz*(CH₂)₂NH(CH₂)₂NH₂)]Br (6) and [Re(CO)₃(κ³-pz*(CH₂)₂S(CH₂)₂NH₂)]Br (7). Complexes 2-7 were characterized by the normal techniques, including x-ray crystallog. anal. in the case of 3, 4, 6 and 7. In these complexes the Re atom adopts a distorted octahedral coordination, being one of the triangular faces defined by the three carbonyl groups and the other three remaining coordination positions by the bidentate and the bromide ligands (3), or by the tridentate and neutral pyrazolyl containing ligands (4, 6, 7). Complexes 2-4, 6 and 7 are static in solution and the 1H NMR data indicate clearly a κ²-coordination mode of the ligand in 2 and 3 and a κ³-coordination in 4, 6 and 7, which agrees with the coordination mode found in the solid state. Compound 5 displays a fluxional behavior in solution as shown by variable temperature 1H NMR studies. No x-ray data exists for this complex but the pattern obtained for the NMR spectrum at 215 K indicates a κ²-coordination mode for the pyrazolyl containing ligand.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:688342 HCAPLUS Full-text

DOCUMENT NUMBER: 132:101913

TITLE: Control of the hapticity of pyridine-2-thiolate
ligands in rhenium(V) oxo complexesAUTHOR(S): Paulo, Antonio; Domingos, Angela;
Santos, IsabelCORPORATE SOURCE: Departamento de Quimica, Estrada Nacional 10, ITN,
Sacavem, 2686-593, Port.SOURCE: Journal of the Chemical Society, Dalton Transactions:
Inorganic Chemistry (1999), (21), 3735-3740

CODEN: JCDBI; ISSN: 0300-9246

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Treatment of [ReO{κ³-B(pz)₄(OMe)₂}] 1 (B(pz)₄ = tetrapyrazolylborate) with pyridine-2-thiol ligands led to [ReO{κ²-B(pz)₄(κ²-Spy*)(OMe)}] (Spy* = 2-

SC5H4N 2 or 2-SC5H3NSiMe3-3 3) or [ReO{κ3-B(pz)4}(κ1-2-SC5H4N)2] 4, depending on the reaction conditions. Complexes 2 and 3 reacted with trimethylsilyl chloride yielding [ReO{κ3-B(pz)4}(κ1-2-SC5H4N)Cl]·HCl 6 and [ReO{κ3-B(pz)4}Cl2], resp. The characterization of the new compds. involves IR and ¹H NMR spectroscopies, x-ray diffraction anal. for 3, 4 and 6.


REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 15 OF 15 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005304949 EMBASE Full-text
 TITLE: Life-threatening ventilatory obstruction due to a defective tracheal tube during spinal surgery in the prone position [8] (multiple letters).
 AUTHOR: Santos, Isabel A., Dr. (correspondence)
 CORPORATE SOURCE: Hospital Geral de Santo Antonio, Porto, Portugal. ialex@mail.telepac.pt
 AUTHOR: Bertaggia, Gregor
 CORPORATE SOURCE: Tyco Healthcare, Hennef, Germany. gregor.bertaggia@emea.tyc ohealthcare.com
 AUTHOR: Oliveira, Carla A.; Ferreira, Leonia; Kennedy, Deirdre
 SOURCE: Anesthesiology, (Jul 2005) Vol. 103, No. 1, pp. 214-215. ISSN: 0003-3022 CODEN: ANESAV
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Letter
 FILE SEGMENT: 024 Anesthesiology
 027 Biophysics, Bioengineering and Medical Instrumentation
 037 Drug Literature Index
 009 Surgery
 LANGUAGE: English
 ENTRY DATE: Entered STN: 29 Sep 2005
 Last Updated on STN: 29 Sep 2005

Structures uploaded into STN REGISTRY

Uploading L1.str



chain nodes :

6 7 8 9 10 11 21 22 23 24 33 34 36 37 38 39 40 41 43 44 45 49

ring nodes :

1 2 3 4 5

ring/chain nodes :

12 13

chain bonds :

1-6 3-33 4-49 5-34 6-7 7-8 8-9 9-10 10-11 22-23 36-43 36-44 37-45 38-39

39-40 39-41

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 1-6 2-3 3-4 3-33 4-5 4-49 5-34 6-7 7-8 8-9 9-10 10-11 36-43 36-44 37-45 38-39 39-40 39-41

exact bonds :

22-23

G1:[*1-*2],[*3-*4]

G2:[*5],[*6],[*7]

G3:H,Cb,Ak

G4:[*8],[*9],[*10]

Hydrogen count :

3:>= minimum 0

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS

10:CLASS

11:CLASS 12:CLASS 13:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 33:CLASS

34:CLASS 36:CLASS

37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 43:CLASS 44:CLASS 45:CLASS

49:CLASS

Full search history

=> d his full

(FILE 'HOME' ENTERED AT 10:16:23 ON 16 DEC 2008)

FILE 'REGISTRY' ENTERED AT 10:16:36 ON 16 DEC 2008

L1 STRUCTURE UPLOADED
 D L1
 L2 0 SEA SSS SAM L1
 L3 12 SEA SSS FUL L1
 D SCAN
 SAVE L3 SCH292L1ST/A

FILE 'HCAPLUS' ENTERED AT 10:19:08 ON 16 DEC 2008

L4 5 SEA SPE=ON ABB=ON PLU=ON L3
 D L4 1-5 TI
 D L4 1-5 AU
 SAVE L4 SCH292HCST/A
 E SANTOS I?/AU
 L5 483 SEA SPE=ON ABB=ON PLU=ON SANTOS I?/AU
 E CORREIA J?/AU
 L6 527 SEA SPE=ON ABB=ON PLU=ON CORREIA J?/AU
 E PAULO A?/AU
 L7 91 SEA SPE=ON ABB=ON PLU=ON PAULO A?/AU
 E ALVES S?/AU
 L8 324 SEA SPE=ON ABB=ON PLU=ON ALVES S?/AU
 E VITOR R?/AU
 L9 20 SEA SPE=ON ABB=ON PLU=ON VITOR R?/AU
 L10 2 SEA SPE=ON ABB=ON PLU=ON L5 AND L6 AND L7 AND L8 AND L9
 L11 56 SEA SPE=ON ABB=ON PLU=ON L5 AND (L6 OR L7 OR L8 OR L9)
 L12 12 SEA SPE=ON ABB=ON PLU=ON L6 AND (L7 OR L8 OR L9)
 L13 8 SEA SPE=ON ABB=ON PLU=ON L7 AND (L8 OR L9)
 L14 3 SEA SPE=ON ABB=ON PLU=ON L8 AND L9
 L15 1366 SEA SPE=ON ABB=ON PLU=ON (L5 OR L6 OR L7 OR L8 OR L9)
 L16 3 SEA SPE=ON ABB=ON PLU=ON L15 AND MALLINCKRODT?/CO,CS,PA,SO
 L17 57 SEA SPE=ON ABB=ON PLU=ON (L11 OR L12 OR L13 OR L14)
 L18 32 SEA SPE=ON ABB=ON PLU=ON L17 AND PYRAZOL?
 L19 28 SEA SPE=ON ABB=ON PLU=ON L17 AND (TRICARBON? OR TRIDENT?)
 L20 5 SEA SPE=ON ABB=ON PLU=ON L10 OR L16
 L21 49 SEA SPE=ON ABB=ON PLU=ON L18 OR L19
 L22 11 SEA SPE=ON ABB=ON PLU=ON L18 AND L19
 L23 14 SEA SPE=ON ABB=ON PLU=ON L20 OR L22
 D L23 1-14 TI
 D L23 1-14 AU
 SAVE TEMP L23 SCH292HCIN/A

FILE 'MEDLINE, BIOSIS, EMBASE, DRUGU' ENTERED AT 10:29:22 ON 16 DEC 2008

L24 0 SEA SPE=ON ABB=ON PLU=ON L10
 L25 16 SEA SPE=ON ABB=ON PLU=ON L23
 SAVE TEMP L25 SCH292MLIN/A
 D STAT QUERY
 D STAT QUERY L4

FILE 'HCAPLUS' ENTERED AT 10:50:00 ON 16 DEC 2008

D L4 1-5 IBIB ED ABS HITSTR

10/551,292

FILE 'MEDLINE, BIOSIS, EMBASE, DRUGU' ENTERED AT 10:50:03 ON 16 DEC 2008

L26 STRUCTURE UPLOADED
 D L26
L27 STRUCTURE UPLOADED
 D L27

FILE 'REGISTRY' ENTERED AT 10:59:32 ON 16 DEC 2008

 D L27
L28 0 SEA SUB=L3 SSS SAM L27
L29 2 SEA SUB=L3 SSS FUL L27
 D L29
 D SCAN
 SAVE L29 SCH292L27ST/A
L30 12 SEA SPE=ON ABB=ON PLU=ON L3 OR L29
 D SCAN

FILE 'HCAPLUS' ENTERED AT 11:03:57 ON 16 DEC 2008

L31 5 SEA SPE=ON ABB=ON PLU=ON L30
L32 5 SEA SPE=ON ABB=ON PLU=ON L31 OR L4
L33 5 SEA SPE=ON ABB=ON PLU=ON L31 AND L4
 D QUE L23
 D QUE L24
 D QUE L25

FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, DRUGU' ENTERED AT 11:06:27 ON 16 DEC 2008

L34 15 DUP REM L23 L25 (15 DUPLICATES REMOVED)
 ANSWERS '1-14' FROM FILE HCAPLUS
 ANSWER '15' FROM FILE EMBASE
 D L34 1-15 IBIB AB

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 DEC 2008 HIGHEST RN 1084385-33-0

DICTIONARY FILE UPDATES: 14 DEC 2008 HIGHEST RN 1084385-33-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Dec 2008 VOL 149 ISS 25
FILE LAST UPDATED: 15 Dec 2008 (20081215/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE MEDLINE

FILE LAST UPDATED: 11 Dec 2008 (20081211/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

MEDLINE Accession Numbers (ANs) for records from 1950-1977 have been converted from 8 to 10 digits. Searches using an 8 or 10 digit AN will retrieve the same record. The 10-digit ANs can be expanded, searched, and displayed in all records from 1949 to the present.

FILE BIOSIS

FILE COVERS 1926 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 10 December 2008 (20081210/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE EMBASE

FILE COVERS 1974 TO 16 Dec 2008 (20081216/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

FILE DRUGU

FILE LAST UPDATED: 12 DEC 2008 <20081212/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<

>>> THESAURUS AVAILABLE IN /CT <<<